. Emanating from the initial hypothesis of Warburg 3 (now known as Warburg's hypothesis), the latest research has revealed that metabolic reprogramming occurs as a consequence of mutations in cancer genes and alterations in cellular signalling. Much of the hype in cancer metabolism comes from the genuine observation that most cancer cells are pro grammed to increase glucose uptake, but to reduce the proportion of glucose oxidized in the Krebs cycle. Rather than oxidizing glu cose for ATP production, glucose in cancer cells tends to be used for anabolic processes, such as ribose production, protein glycosy lation and serine synthesis [4] [5] [6] [7] . Cancer cells use additional nutritional inputs for anabo lism besides glucose. From its metabolism to pyruvate, glutamine is key for providing reduced NADPH, which is needed for lipid synthesis, and to refill the Krebs cycle (ana plerosis) 8, 9 . The control of this pathway by key oncogenes, such as MYC and mutant RAS, has further enforced the importance of this route in cancer. This view of cancer metabolism takes the focus away from ATP as the key product of glucose and glutamine catabolism. The fact is that in most bio logical contexts (but not all, as we discuss below), ATP production is sufficient for cancer cell function.
In addition to glucose and glutamine, fatty acids are an extremely relevant energy source. They can be incorporated from the extracellular media, or can be potentially obtained from hydrolysed triglycerides (in cells accumulating lipid droplets) by neutral (N) hydrolases in the cytoplasm or acid (A) hydrolases through a novel autophagic pathway: lipophagy 10 . De novo synthesis of fatty acids is required for mem brane synthesis and therefore for cell growth and proliferation. Fatty acid synthesis is an anabolic process that starts from the con version of acetyl CoA to malonyl CoA by acetyl CoA carboxylase. Malonyl CoA is then committed to fatty acid synthesis (FAS) and is involved in the elongation of fatty acids through fatty acid synthase (FASN). Additional modifications of fatty acids can be carried out by elongases and desaturases. Fatty acids are catabolized by the fatty acid oxidation (FAO; also known as βoxidation) pathway.
With most cancer researchers focusing on glycolysis, glutaminolysis and fatty acid syn thesis, the relevance of FAO for cancer cell function has not been carefully examined, and its relevance has remained obscure. However, studies in the past 4 years have started to bring to light a relevant role for this metabolic pathway in cancer, and this is accompanied by new and exciting therapeu tic implications. The focus of this Progress article is to enumerate, highlight and inte grate these recent findings into our current understanding of metabolic reprogramming in cancer cells.
Extra ATP when needed
Relative to their dry mass, fatty acids pro vide twice as much ATP as carbohydrates (six times more when comparing stored fatty acids to stored glycogen), and in turn they are the preferred nutrient for storage (in the form of triglycerides in adipose tissue) under conditions of nutrient abundance. FAO is composed of a cyclical series of reactions that result in the shortening of fatty acids (two carbons per cycle) and that generate in each round NADH, FADH 2 and acetyl CoA, until the last cycle when two acetyl CoA molecules are originated from the catabolism of a fourcarbon fatty acid (FIG. 1) . NADH and FADH 2 that are generated by FAO enter the electron transport chain (ETC) to produce ATP (FIG. 2) . FAO is car ried out in energydemanding tissues (such as the heart and skeletal muscle) and in the liver as a central organ for nutrient supply and conversion.
We have summarized the metabolic switch as a programme in which the utiliza tion of metabolic intermediates for anabo lism prevails beyond ATP production. But there are situations in which cancer cells seem to require increased ATP production. This is exemplified by loss of attachment (LOA) to the extracellular matrix. Cells derived from solid tumours that undergo LOA display inhibition of glucose uptake and catabolism, which results in the loss of ATP, NADPH (as a result of decreased flux through the pentose phosphate pathway (PPP)) and increased production of reac tive oxygen species (ROS) (FIG. 3) . Schafer and coworkers 11 showed that in these settings ROS inhibit FAO, and that antioxi dants counteract ROS accumulation and can reactivate FAO, increase ATP levels and prevent LOAinduced anoikis, although the exact mechanism by which an increase in ATP rescues anoikis remains unclear. Abstract | Warburg suggested that the alterations in metabolism that he observed in cancer cells were due to the malfunction of mitochondria. In the past decade, we have revisited this idea and reached a better understanding of the 'metabolic switch' in cancer cells, including the intimate and causal relationship between cancer genes and metabolic alterations, and their potential to be targeted for cancer treatment. However, the vast majority of the research into cancer metabolism has been limited to a handful of metabolic pathways, while other pathways have remained in the dark. This Progress article brings to light the important contribution of fatty acid oxidation to cancer cell function. The relevance of FAO for cell survival on LOA was further supported by findings from the Pandolfi laboratory 12 . They described a novel mechanism in which FAO is regulated by the promyelocytic leukaemia (PML) protein, and this regulation is dependent on peroxisome proliferatoractivated receptors (PPARs). In agreement with the study from Joan Brugge's group 11 , the ability of PML to increase FAO activity promoted cell survival on LOA. This mechanism of action provides an explanation for the upregulation of PML that is observed in a subset of aggressive breast cancers with increased PPAR activity and a poor prognosis 12 .
The requirement of FAO for ATP pro duction in conditions of metabolic stress is recapitulated in other cancer types and conditions. The group of Tak W. Mak 13 identified an atypical carnitine palmitoyl transferase 1 (CPT1) isoform -CPT1C -as a potential oncogene 13 . CPT1 con jugates fatty acids with carnitine to trans locate them to the mitochondria, where the acylcarinitines undergo FAO. CPT1C is normally primarily expressed in the brain, but these authors found that CPT1C expression in cancer cells promoted FAO and ATP production, tumour growth, res cue from metabolic stress and resistance to mTOR complex 1 (mTORC1) inhibitors. Despite this newly identified oncogenic activity of CPT1C, information regarding its subcellular localization and its substrate specificity is limited and warrants further study [14] [15] [16] . FAO is also relevant to cells that do not undergo LOAinduced metabolic stress, such as lymphoma and leukaemia cells (FIG. 3) . The group of Michael Andreeff 17 suggested that the FAO pathway is not rel evant for the production of ATP in certain leukaemias 17 . Instead, FAO is required for cell survival and may influence BAX and BAKdependent mitochondrial perme ability transition pore formation 17 . Proteins involved in FAO, such as CPT1, have been shown to have an antiapoptotic function that is attributed to crosstalk with the BH3 family of proapoptotic proteins 18, 19 . Although the BH3regulatory activity of proteins involved in FAO (presum ably CPT1 (REFS 18, 19) ) is thought to be instrumental in promoting the survival of certain leukaemia cells 17 , this might not be the whole story. FAO inhibition leads to a cytotoxic increase of lipids, and preventing this cytotoxicity might also be a contribut ing factor 17, 20 . Additional papers have also shown that the excessive production of FAOderived ATP is detrimental to the survival of leukaemia cells, and that this might be avoided through an increase in the expression of mitochondrial uncoupling proteins (UCP2 and UCP3) 21 . UCPs are mitochondrial anion carriers at the inner mitochondrial membrane. UCPs dissipate the proton gradient, therefore reducing the yield of ATP from oxidative phosphorylation (OXPHOS). UCP2 and UCP3 seem to regulate the production of free radicals, and they are also involved in insulin secretion and fatty acid metabolism, respectively. The catalytic activity of UCP1 is unclear. It might be a fatty acidactivated proton carrier or a flippase of protonated fatty acids to the inner mitochondrial side (which results in the loss of the proton gradient).
Recent studies in diffuse large B cell lymphoma (DLBCL) show a more complex picture. The group of Nika Danial 22 recently found that a previously defined subset of DLBCLs that do not require the activa tion of the B cell receptor for survival have an OXPHOS gene expression signature 22 , indicating that they are highly dependent on mitochondrial metabolism for survival 23 . This DLBCL subtype catabolizes fatty acids at a higher rate than other subtypes of DLBCL and is highly dependent on FAO for survival and growth. In this cellular system, Figure 1 | Representation of the β-oxidation of palmitic acid in the mitochondria. AcylCoAs enter the fatty acid oxidation (FAO) pathway in which they are dehydrogenated, hydrated and decarboxylated cyclically, which results in the progressive shortening of the fatty acid. The production of NADH and FADH 2 will be used for ATP production in the electron transport chain, and acetyl CoA can enter the Krebs cycle. S-CoA, free coenzme A.
Glossary

Anoikis
An apoptotic process activated as a result of insufficient or inadequate cell-matrix interactions. This process can be observed during development and epithelial hyperproliferation or can be induced experimentally.
Fatty acid synthase
(FASN). This protein has eight different enzymatic activities in a single polypeptidic chain and gives rise to palmitic acid (16:0).
Oxidative phosphorylation
(OXPHOS). The oxidation of reduced NAD and FAD for the production of ATP, creating an exchange of electrons between donors and acceptors (oxygen) and a proton gradient between the intermembrane space and the lumen of the mitochondria. This process is carried out by the electron transport chain at the inner mitochondrial membrane and favours the generation of ATP by ATP synthase while dissipating the proton gradient.
Pentose phosphate pathway (PPP). This metabolic pathway generates pentoses and NADPH, which are both required for cell growth and proliferation. Through its oxidative branch, glucose-6-phosphate is oxidized to generate ribulose-5-phosphate (for nucleotide synthesis) and NADPH for anabolism.
Warburg's hypothesis
Otto Warburg observed that cancer cells, in the presence of oxygen, metabolize glucose anaerobically, leading to the production of lactate, instead of oxidizing it through the Krebs cycle. Thus, he hypothesized that cancer cells had dysfunctional mitochondria, and this metabolic rewiring was termed the Warburg effect. fatty acids are responsible for the majority of cellular respiration, a large proportion of ATP production and potentially the recy cling of reduced glutathione (GSH) to cope with oxidative stress (as discussed below). Recent evidence suggests that normal and cancer stem cells benefit from active FAO for their maintenance and function. Samudio et al. 17 suggested that inhibition of FAO could affect leukaemia progenitor cells or leukaemiainitiating cells (LICs). In a more recent study, Ito, Carracedo et al. 24 characterized the contribution of FAO downstream of PML and PPARδ to the maintenance and function of haematopoietic stem cells (HSCs) and potentially to LICs. They showed that PPARδ is required for the maintenance of HSCs, a function that is associated with FAOderived ATP pro duction. This PML-PPAR-FAO axis that Pandolfi and colleagues initially described is involved in HSC maintenance through the regulation of asymmetric cell division. Pharmacological or genetic interference at any level in this pathway unequivocally resulted in the exhaustion of the stem cell pool. It is worth noting that the genetic abla tion of another FAOregulatory protein, liver kinase B1 (LKB1; also known as STK11) similarly results in the exhaustion of the HSC pool [25] [26] [27] . In addition, a recent report has demonstrated that neuronal stem and progenitor cells (NSPCs) require FAS to Figure 2 | Effect of FAO on cancer cell metabolism, growth and survival. A schematic representation of the metabolic routes interconnected with fatty acid oxidation (FAO) is shown. Central metabolic processes are depicted such as glycolysis, the pentose phosphate pathway (PPP), the Krebs cycle, the electron transport chain (ETC) and FAO. Fatty acids for FAO can either be of extracellular origin (through a first shortening in the peroxisomal FAO for very long fatty acids) or be obtained through the metabolism of triglycerides from lipid droplets. The fate of FAO products is summarized. NADH and FADH 2 are oxidized in the ETC for ATP production and acetyl CoA enters the Krebs cycle to produce citrate, which can be exported to the cytoplasm to engage NADPH-producing reactions. Importantly, the accumulation of fatty acids that do not undergo β-oxidation can induce lipotoxicity. Of note, FAO-independent activities of components in this route are depicted. Dashed arrows represent indirect effects or serial reactions. 6PGLDH, 6-phosphogluconate dehydrogenase; α-KG, α-ketoglutarate; ACC, acetyl CoA carboxylase; AMPK, AMP kinase; CPT1, carnitine palmitoyltransferase; FASN, fatty acid synthase; G6PDH, glucose-6-phosphate dehydrogenase; IDH1, isocitrate dehydrogenase 1; ME1, malic enzyme; PC, pyruvate carboxylase; PDK, pyruvate dehydrogenase (PDH) kinase; PEP, phosphoenol pyruvate; PPAR, peroxisome proliferator-activated receptor; UCP, uncoupling protein. FAO is an important source of NADPH As stated above, cancer cells are depend ent on ATP production for survival only in certain conditions. In the majority of situations, however, the potential of cancer cells to grow and survive will be limited by the levels of cytosolic NADPH. Therefore, metabolic reprogramming must meet the requirement of producing reduced NADP + . This is achieved in four main enzy matic reactions: the oxidation of glucose through glucose6phosphodehydrogenase (G6PDH) and 6phosphogluconolactone dehydrogenase (6PGLDH) in the PPP; the metabolism of malate to pyruvate that is catalysed by malic enzyme (ME1); and the oxidation of isocitrate to αketoglutarate by isocitrate dehydrogenase (IDH1) (FIG. 2) . NADPH exerts two main functions in the cell 30 . On the one hand, it provides redox power to counteract oxidative stress, which has proved to be crucial for cancer cell survival in conditions of metabolic stress. On the other hand, it is a coenzyme for anabolic enzymes, and is thus key for the generation of new building blocks to sustain cell growth and proliferation.
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How is FAO relevant to the produc tion of NADPH? As described above, FAO generates one molecule of acetyl CoA in each oxidation cycle and two in the last cycle (FIG. 1) . Acetyl CoA enters the Krebs cycle, and together with oxaloacetate gives rise to citrate, which on export to the cytoplasm, can enter two metabolic chain reactions that produce cytosolic NADPH (FIG. 2) . The production of FAOderived cytosolic NADPH by cancer cells is key to counteract oxidative stress. For example, glioma cells in which FAO is inhibited exhibit a profound decrease in NADPH levels, accumulate increased levels of ROS and undergo cell death 31 . The relevance of FAO for NADPH homeostasis has been recently investigated by the group of Nissim Hay 32 . On metabolic stress, FAO serves to sustain ATP levels and NADPH produc tion 11, 13, 32 . They observed that availability of NADPH is controlled by the LKB1-AMP kinase (AMPK) axis. AMPK is involved in maintaining the equilibrium of NADPH consuming (FAS) and NADPHproducing (FAOderived) reactions. AMPK promotes FAO through the inhibitory phosphoryla tion of acetyl CoA carboxylase (ACC) 33 , and potentially through the regulation of PPAR signalling 34 and CPT1C expression 13 . Therefore, although the LKB1-AMPK axis is thought to be tumour suppressive, AMPK activity is essential for a cancer cell to 'sense' stressful environments and to respond by activating a catabolic switch that increases ATP and NADPH reserves.
FAOdependent NADPH produc tion could also be relevant to the survival of leukaemia cells 17, 23, [25] [26] [27] , although this possibility has not been formally tested. Indeed, in the haematopoietic lineage, it is well established that HSCs are extremely sensitive to ROS levels [35] [36] [37] . Increased levels of ROS result in a loss of maintenance and exhaustion of HSCs. As FAOregulatory pathways are also relevant for the main tenance of this cell subpopulation, it is tempting to speculate that FAO could provide stem cells with the NADPH required to prevent ROS from driving cell differentiation.
Perspectives
Cancer metabolism can be perceived as a network of pathways with plasticity, feed back loops and crosstalk that ensure the fitness of tumour cells. Plasticity is key, and FAO might provide some of this plastic ity by enabling the production of ATP and NADPH when required, eliminating poten tially toxic lipids, inhibiting proapoptotic pathways and providing metabolic inter mediates for cell growth. However, FAO can not be perceived as a metabolic pathway that is active independently of the microenviron ment of the cancer cell. Indeed, in ovarian cancers, which have a predilection to metas tasize to the omentum (an adipocyterich tissue), the interaction with adipocytes is necessary for the transfer of lipids to the can cer cell, the activation of FAO and the establishment of metastasis 38 . A big challenge is to unify the idea of FAO as an essential pathway in cancer cells with the fact that cancer cells also require active FAS in order to grow and divide. Dogma states that FAO and FAS are incom patible. In principle, ACC determines which pathway is active, on the basis of acetyl CoA and malonyl CoA levels. Therefore, as ACC is a 'oneway street' , both metabolic activities cannot coexist. However, we might need to rethink such a rigid regulatory framework. The group of Nissim Hay 32 showed that genetic manipulation of ACC1 or ACC2 in cancer cells yielded different outcomes in terms of FAS and FAO. In addition, FAO metabolism can contribute to the accumula tion of acetyl CoA in the cytoplasm that is needed to initiate FAS, so that FAS and FAO can support each other 23 . On the basis of this idea, we can speculate that, rather than a total pool of acetyl CoA and malonyl CoA, there might be ACC1 and ACC2 localiza tiondependent compartmentalization 39 of these metabolites that allows both metabolic pathways to be active simultaneously and independently from each other.
The data suggesting a greater require ment of FAO in undifferentiated cells also raise an interesting possibility. It is plausible that in quiescent and undifferen tiated cells the competition between FAS and FAO may be less prominent (as these cells display a lower membrane synthe sis rate), thus indicating that these cells might derive a full survival benefit from FAO activation and its biological output. In turn, their dependence on FAO could make them vulnerable, providing a unique therapeutic opportunity from the pharma cological manipulation of this metabolic pathway.
For all the reasons stated above, there is an exciting therapeutic potential for the pharmacological blockade of FAO in cancer. Two key enzymes in the FAO pathway are particularly interesting as potential targets for pharmacological intervention. CPT1 is considered the ratelimiting enzyme in FAO and can be pharmacologically tar geted. Drugs that target 3ketoacylthiolase (3KAT), which catalyses the final step in FAO, are also available (TABLE 1) .
The pharmacological blockade of FAO has been pursued for the treatment of heart diseases. As a consequence, FAO inhibi tors have been approved for human use. Perhexiline, a CPT1 inhibitor, has been approved in Australia and some Asian coun tries for the treatment of heart disease. Other CPT1 inhibitors either exhibited toxic side effects in clinical trials (etomoxir treatment in patients results in hepatotoxicity 40 but has promising antitumoural effects in mice 17 ) or are still at the preclinical stage (oxfenicine). Trimetazidine 41 and ranolazine 42 , which are 3KAT inhibitors, are both licensed in Europe for the treatment of angina, as is trimetazidine in Asia and ranolazine in the United States. Notably, other nonclinical compounds that activate FAO have been tested in cell culture models and mice 12, 23, 24, 32 (TABLE 1), and could be useful to elucidate the contribution of FAO to tumour cell survival.
FAO can be indirectly activated by PPAR activators, AMPK activators or ACC inhibi tors, or by exposing cells to high concentra tions of fatty acids and carnitine. Although these indirect mechanisms for FAO activa tion are useful, the variety of pathways that become activated by these approaches complicates the interpretation of the results.
In summary, the study of FAO in the context of cancer metabolism has unveiled new and exciting therapeutic opportunities, together with a more profound comprehen sion of the metabolic wiring of cancer cells. We have learned over the past few decades that targeting single enzymes or pathways rarely results in cures for cancer, so it is likely that agents that target FAO will need to be combined with chemotherapies or with other targeting agents to be successful. Clearly, further knowledge of the depend ence of cancer cells on FAO will be necessary to refine rational approaches to combination therapies that target fatty acid catabolism. 
